Low-Dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Septic Patients
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Delirium is common in septic patients, especially those receiving mechanical ventilation in
the intensive care unit (ICU). Dexmedetomidine is a highly selective α2 adrenoreceptor
agonist with anxiolytic, sedative, analgesic, and anti-inflammatory effects. Use of
dexmedetomidine in mechanically ventilated ICU patients is associated with less delirium and
improved outcomes. However, dexmedetomidine infusion produces dose-dependent bradycardia and
hypotension; these limited the use of dexmedetomidine in ICU patients. This study is designed
to test the hypothesis that low-dose dexmedetomidine infusion can also reduce delirium in
mechanically ventilated ICU patients with sepsis.
Phase:
N/A
Details
Lead Sponsor:
Peking University First Hospital
Collaborators:
Beijing Friendship Hospital Beijing Hospital Beijing Shijitan Hospital, Capital Medical University Beijing Tongren Hospital China-Japan Friendship Hospital